The Experts below are selected from a list of 3189 Experts worldwide ranked by ideXlab platform
Saul Suster - One of the best experts on this subject based on the ideXlab platform.
-
Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus
Modern Pathology, 2018Co-Authors: David Suster, German Pihan, Alexander C. Mackinnon, Saul SusterAbstract:Poorly differentiated non-keratinizing squamous cell carcinoma of the thymus, also known as Lymphoepithelioma-like carcinoma, is a rare primary malignant neoplasm of thymic origin. The mainstay of treatment for these tumors is surgical and they tend to respond poorly to chemotherapy. The checkpoint programmed cell death ligand-1 protein (PD-L1) bound to its receptor (PD-1) has been demonstrated to be an important therapeutic target for many different tumors. Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus may indicate that these tumors are potential targets for inhibitor therapy. Twenty-one cases of Lymphoepithelioma-like carcinoma of the thymus were collected and reviewed. Tissue microarrays were created using triplicate 2 mm cores for each case. PD-L1/PD-1 staining pattern (neoplastic cells versus tumor infiltrating lymphocytes) was documented for each case. Out of 21 cases, 15 (71.4%) showed various degrees of membranous PD-L1 staining. Of the positive cases, 48% showed high expression of PD-L1 (>50% of tumor cells) and 24% showed low expression (
David Suster - One of the best experts on this subject based on the ideXlab platform.
-
Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus
Modern Pathology, 2018Co-Authors: David Suster, German Pihan, Alexander C. Mackinnon, Saul SusterAbstract:Poorly differentiated non-keratinizing squamous cell carcinoma of the thymus, also known as Lymphoepithelioma-like carcinoma, is a rare primary malignant neoplasm of thymic origin. The mainstay of treatment for these tumors is surgical and they tend to respond poorly to chemotherapy. The checkpoint programmed cell death ligand-1 protein (PD-L1) bound to its receptor (PD-1) has been demonstrated to be an important therapeutic target for many different tumors. Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus may indicate that these tumors are potential targets for inhibitor therapy. Twenty-one cases of Lymphoepithelioma-like carcinoma of the thymus were collected and reviewed. Tissue microarrays were created using triplicate 2 mm cores for each case. PD-L1/PD-1 staining pattern (neoplastic cells versus tumor infiltrating lymphocytes) was documented for each case. Out of 21 cases, 15 (71.4%) showed various degrees of membranous PD-L1 staining. Of the positive cases, 48% showed high expression of PD-L1 (>50% of tumor cells) and 24% showed low expression (
Alexander C. Mackinnon - One of the best experts on this subject based on the ideXlab platform.
-
Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus
Modern Pathology, 2018Co-Authors: David Suster, German Pihan, Alexander C. Mackinnon, Saul SusterAbstract:Poorly differentiated non-keratinizing squamous cell carcinoma of the thymus, also known as Lymphoepithelioma-like carcinoma, is a rare primary malignant neoplasm of thymic origin. The mainstay of treatment for these tumors is surgical and they tend to respond poorly to chemotherapy. The checkpoint programmed cell death ligand-1 protein (PD-L1) bound to its receptor (PD-1) has been demonstrated to be an important therapeutic target for many different tumors. Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus may indicate that these tumors are potential targets for inhibitor therapy. Twenty-one cases of Lymphoepithelioma-like carcinoma of the thymus were collected and reviewed. Tissue microarrays were created using triplicate 2 mm cores for each case. PD-L1/PD-1 staining pattern (neoplastic cells versus tumor infiltrating lymphocytes) was documented for each case. Out of 21 cases, 15 (71.4%) showed various degrees of membranous PD-L1 staining. Of the positive cases, 48% showed high expression of PD-L1 (>50% of tumor cells) and 24% showed low expression (
German Pihan - One of the best experts on this subject based on the ideXlab platform.
-
Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus
Modern Pathology, 2018Co-Authors: David Suster, German Pihan, Alexander C. Mackinnon, Saul SusterAbstract:Poorly differentiated non-keratinizing squamous cell carcinoma of the thymus, also known as Lymphoepithelioma-like carcinoma, is a rare primary malignant neoplasm of thymic origin. The mainstay of treatment for these tumors is surgical and they tend to respond poorly to chemotherapy. The checkpoint programmed cell death ligand-1 protein (PD-L1) bound to its receptor (PD-1) has been demonstrated to be an important therapeutic target for many different tumors. Expression of PD-L1/PD-1 in Lymphoepithelioma-like carcinoma of the thymus may indicate that these tumors are potential targets for inhibitor therapy. Twenty-one cases of Lymphoepithelioma-like carcinoma of the thymus were collected and reviewed. Tissue microarrays were created using triplicate 2 mm cores for each case. PD-L1/PD-1 staining pattern (neoplastic cells versus tumor infiltrating lymphocytes) was documented for each case. Out of 21 cases, 15 (71.4%) showed various degrees of membranous PD-L1 staining. Of the positive cases, 48% showed high expression of PD-L1 (>50% of tumor cells) and 24% showed low expression (
Weineng Feng - One of the best experts on this subject based on the ideXlab platform.
-
a multicenter analysis of genomic profiles and pd l1 expression of primary Lymphoepithelioma like carcinoma of the lung
Modern Pathology, 2020Co-Authors: Zhanhong Xie, Laiyu Liu, Xinqing Lin, Xiaohong Xie, Ming Liu, Jiexia Zhang, Ming Ouyang, Analyn Lizaso, Hua Zhang, Weineng FengAbstract:To understand the molecular mechanism of tumorigenesis of pulmonary Lymphoepithelioma-like carcinoma and explore potential therapeutic strategies, we investigated the genomic profiles and PD-L1 expression of 29 Chinese pulmonary Lymphoepithelioma-like carcinoma patients at various stages. We performed capture-based targeted sequencing on tissue samples collected from 27 patients with sufficient samples using a panel consisting of 520 cancer-related genes, spanning 1.64 Mb of the human genome. We identified 184 somatic mutations in 109 genes from 26 patients. One patient had no mutations detected by this panel. Copy number variations were detected in 52% (14/27) of the patients, with a majority having advanced-stage disease (10/14). Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected. Interestingly, 78% (21/27) of the patients had mutations in epigenetic regulators. Of the 184 mutations identified, 51 occurred in 29 epigenetics-related genes. Furthermore, we performed PD-L1 immunohistochemistry staining using the Dako 22C3 assay and demonstrated that 69% (20/29) of the cohort had positive PD-L1 expression, of which three patients received and benefited from a PD-1 inhibitor. In conclusion, we elucidated a distinct genomic landscape associated with pulmonary Lymphoepithelioma-like carcinoma with no classic lung cancer driver mutation but an enrichment of mutations in epigenetic regulators. The detection of high PD-L1 expression and lack of any canonical druggable driver mutations raises the potential of checkpoint immunotherapy for pulmonary Lymphoepithelioma-like carcinoma.
